The Technical Analyst
Satsuma Pharmaceuticals [STSA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Satsuma Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $1.100
America/New_York / 7 jun 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 36.47 mill |
| EPS: | -1.990 |
| P/E: | -0.553 |
| Earnings Date: | Aug 07, 2023 |
| SharesOutstanding: | 33.15 mill |
| Avg Daily Volume: | 1.107 mill |
| RATING 2023-06-07 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.553 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.553 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.049 - 1.151 ( +/- 4.64%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-08 | Ra Capital Management, L.p. | Sell | 5 914 252 | Common Stock |
| 2023-06-08 | Ra Capital Management, L.p. | Sell | 10 000 | Stock Option (Right to Buy) |
| 2023-06-08 | Ra Capital Management, L.p. | Sell | 20 000 | Stock Option (Right to Buy) |
| 2023-06-08 | Ra Capital Management, L.p. | Sell | 30 000 | Stock Option (Right to Buy) |
| 2023-06-06 | O'neil Thomas P. | Sell | 13 877 | Common Stock, $0.0001 par value |
| INSIDER POWER |
|---|
| 54.69 |
| Last 97 transactions |
| Buy: 62 291 817 | Sell: 17 994 879 |
Forecast:
01:40 - $1.016
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.100 (0.00% ) |
| Volume | 1.826 mill |
| Avg. Vol. | 1.107 mill |
| % of Avg. Vol | 165.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For STSA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
STSA
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2022-09-06 08:02:00 - Press Release
Satsuma Pharmaceuticals To Present At The H.c. Wainwright 24th Annual Global Investment Conference
South san francisco, calif., sept. 06, 2022 (globe newswire) -- satsuma pharmaceuticals, inc. (nasdaq: stsa), a clinical-stage biopharmaceutical company developing sts101 (dihydroergotamine (dhe) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that john kollins, its president and chief executive officer, will present a corporate overview at the h.c. wainwright 24th annual global investment conference being held september 12-14, 2022, both virtually and in-person at the lotte new york palace hotel.
2022-05-11 16:05:00 - Press Release
Satsuma Pharmaceuticals To Present At The H.c. Wainwright Global Investment Conference
South san francisco, calif., may 11, 2022 (globe newswire) -- satsuma pharmaceuticals, inc. (nasdaq: stsa), a clinical-stage biopharmaceutical company developing sts101 (dihydroergotamine (dhe) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that john kollins, its president and chief executive officer, will present at the h.c. wainwright global investment conference and invites investors to participate via webcast or in-person in miami, fl on may 24 -25, 2022. please see additional details below:
2022-02-08 08:30:00 - Press Release
Satsuma Pharmaceuticals To Present At The Virtual 11th Annual Svb Leerink Global Healthcare Conference
South san francisco, calif., feb. 08, 2022 (globe newswire) -- satsuma pharmaceuticals, inc. (nasdaq: stsa), a clinical-stage biopharmaceutical company developing sts101 (dihydroergotamine (dhe) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that john kollins, its president and chief executive officer, will present at the 11th annual svb leerink global healthcare conference and invites investors to participate via webcast. please see additional details below:
2021-10-12 16:15:00 - Press Release
Satsuma Pharmaceuticals Announces The Appointment Of mutya Harsch To Its Board Of Directors
South san francisco, calif., oct. 12, 2021 (globe newswire) -- satsuma pharmaceuticals, inc. (nasdaq: stsa), a clinical-stage biopharmaceutical company developing sts101 (dihydroergotamine (dhe) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced the appointment of mutya harsch, jd to its board of directors, effective immediately. ms. harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to satsuma. she currently serves as general counsel, chief legal officer and secretary of vyne therapeutics, a publicly traded biopharmaceutical company.
2021-09-28 16:05:00 - Press Release
Satsuma Pharmaceuticals To Present At The Cantor Virtual Global Healthcare Conference
South san francisco, calif., sept. 28, 2021 (globe newswire) -- satsuma pharmaceuticals, inc. (nasdaq: stsa), a clinical-stage biopharmaceutical company developing sts101 (dihydroergotamine (dhe) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that john kollins, its president and chief executive officer, is scheduled to present at the cantor virtual global healthcare conference and invites investors to participate via webcast and in one-on-one meetings. please see additional details below:
Latest News
2022-11-25 09:43:55 - PennyStocks
Best Penny Stocks To Buy Now? 7 Insider Picks In November
7 penny stock picks from insiders in November 2022 The post Best Penny Stocks To Buy Now? 7 Insider Picks In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-21 10:06:51 - PennyStocks
Penny Stocks To Buy: 7 Insider Picks For November 2022
Penny stocks to buy according to insiders in November 2022. The post Penny Stocks To Buy: 7 Insider Picks For November 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-14 11:40:52 - InvestorPlace
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?
The focus in the world of drugmakers is on Satsuma Pharmaceuticals (NASDAQ: STSA ) right now, but not in a good way. Specifically, the company's proposed treatment for migraine headaches didn't meet its “primary endpoints,” as they say.
2022-09-06 08:02:00 - GlobeNewsWire
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel.
2022-05-11 16:05:00 - GlobeNewsWire
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference and invites investors to participate via webcast or in-person in Miami, FL on May 24 -25, 2022. Please see additional details below:
2022-02-08 08:30:00 - GlobeNewsWire
Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference and invites investors to participate via webcast. Please see additional details below:
2021-10-12 16:15:00 - GlobeNewsWire
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced the appointment of Mutya Harsch, JD to its Board of Directors, effective immediately. Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma. She currently serves as General Counsel, Chief Legal Officer and Secretary of VYNE Therapeutics, a publicly traded biopharmaceutical company.
2021-09-28 16:05:00 - GlobeNewsWire
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:
2021-09-08 16:05:00 - GlobeNewsWire
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in one-on-one meetings with investors. The Conference will be held virtually with all participants joining remotely from September 13th – 15th.
2021-08-10 16:05:00 - GlobeNewsWire
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-